Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) presented encouraging interim data for its Phase 2 clinical trial of poziotinib to treat EGFR Exon 20 Mutant Non-Small Cell Lung Cancer. The stock price leaped $5.21 to close at $19.67.
Spectrum Pharmaceuticals presents encouraging data
October 18, 2017 at 17:34 PM EDT
